在心力衰竭中,ALPK2 能够通过保存的喷射分数来预防心脏透气功能障碍
Tatsuya Yoshida1, Satoya Yoshida1, Kohei Inukai1
1Department of Cardiology, Nagoya University School of Medicine, Nagoya, Japan.
概括
阿尔法激酶2 (ALPK2) 是一种新的心脏特异性激酶. 缺少ALPK2会在衰老和心力衰竭中恶化心脏透功能障碍,这表明它是一个治疗标.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 生物化学 生化学
背景情况:
- 蛋白质酸化调节心脏功能,但扩张性机制尚不清楚.
- 保存喷射分数 (HFpEF) 的心力衰竭涉及心脏透支功能障碍,其潜在机制尚不清楚.
- 心脏蛋白激酶是关键的调节者,但它们在腹痛中所扮演的特定角色需要阐明.
研究的目的:
- 调查心脏蛋白激酶在心脏功能,特别是腹筋功能中的作用.
- 为了识别参与心力衰竭的新型心脏特异性激酶与保存的射出分数 (HFpEF).
- 评估α-酶2 (ALPK2) 作为扩张性功能障碍的潜在治疗标.
主要方法:
- 在人体组织中分析了518种蛋白激酶的基因表达.
- 产生了心肌细胞特异性Alpk2-淘汰和Alpk2-过度表达的小鼠模型.
- 在各种疾病模型中评估心脏功能,包括衰老,心肌梗塞,压力过载和HFpEF.
主要成果:
- 确定了α-激酶2 (ALPK2) 作为一种新的心脏特异性非典型激酶.
- Alpk2 缺乏症加剧了年龄和HFpEF 诱导的心脏扩张功能障碍.
- 在HFpEF中,Alpk2过度表达减轻了心脏硬性和增加了Tropomyosin 1酸化.
结论:
- ALPK2在调节心脏扩张功能方面发挥着至关重要的作用.
- 在老化和HFpEF中,ALPK2缺乏会加剧心脏透静功能障碍.
- ALPK2是治疗心脏透支功能障碍和与年龄有关的心脏损伤的有前途的治疗标.
更多相关视频
07:49Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
1.3K
08:31Isolation of Atrial Cardiomyocytes from a Rat Model of Metabolic Syndrome-related Heart Failure with Preserved Ejection Fraction
Published on: July 26, 2018
10.1K
相关概念视频
01:22Heart Failure Drugs: Diuretics
345
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
345
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
391
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
391
01:22Heart Failure Drugs: β-Blockers
319
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
319
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inotropic Agents
523
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
523